Propanc Biopharma (PPCB)  has a reason to get excited.

With a promising treatment for solid tumor cancers coming down its pipeline, the early stage healthcare company has its sights set on changing the way cancer is treated.

CEO James Nathanielsz told TheStreet at the LD Micro conference in Los Angeles that his firm is in the right place to develop treatment for the kind of tumor that affects 8% of cancer patients.

Nathanielsz also explained how Propanc is restructuring its debt in order to stoke optimism in investors while the company's most promising drug is still in development. 

For more from the LD Micro Conference in La:

TheStreet at LD Micro: What CEO Dave Callaway Sees in Small Caps This Year

STK Owner The ONE Group Is Carving Its Own Unique Space in the Dining Experience

SRAX Chief Weighs in as Company Readies for Cryptocurrency Dividend

Snap Interactive's New Blockchain App Could Flip Video Chat on Its Head

Micro Caps Take the Spotlight at LD Micro Conference - Here's What to Expect

Lexaria Biosciences Is Ready for the Legal Cannabis Boom

Here's How Small Cap Scissor Company Acme United Is Benefitting From Amazon

Here's How Cloud Computing Firm Fusion Is Using M&A to Get Ahead

Biotech Innovator Oncolix Utilizing Novel Treatment to End Women's Cancers

Amazing Energy Isn't Afraid to Take on Big Oil